)
Visual
test
BioAge Labs
BioAge Labs (BIOA) investor relations material
BioAge Labs Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary20 Jan, 2026
Platform and strategy
Focuses on developing therapies for metabolic diseases by harnessing human aging biology and large-scale molecular data sets, with over 150 million data points and 25,000+ profiles tracked for 50+ years.
Validated discovery platform with ongoing pharma collaborations, including Novartis and Lilly, to identify novel drug targets related to exercise and healthy aging.
Supported by a leadership team with extensive biopharma experience and a strong board, including former CEOs and managing partners from leading pharma and investment firms.
Lead program: BGE-102 (NLRP3 inhibitor)
BGE-102 is an oral, brain-penetrant NLRP3 inhibitor with a unique, patented binding site and novel mechanism, showing best-in-class potency and safety in Phase 1 trials.
Demonstrated >90% suppression of IL-1β and 86% reduction in hsCRP in obese subjects, with 93% achieving normalized hsCRP (<2 mg/L), aligning with injectable anti-inflammatories.
Well-tolerated with only mild/moderate, self-limited adverse events and a wide safety margin.
Strong intellectual property position with composition of matter protection through 2045.
Clinical development and results
Phase 1 trials included healthy volunteers and obese participants, showing dose-proportional pharmacokinetics and sustained pharmacodynamic effects.
In obese cohorts, BGE-102 led to 86% reduction in hsCRP, 44-62% reduction in IL-6, 30% reduction in fibrinogen, and 93% suppression of IL-1β at trough.
Achieved therapeutic concentrations in CSF, supporting potential for CNS indications.
Planned Phase 2a proof-of-concept in obesity and cardiovascular risk, with endpoints including hsCRP, metabolic parameters, and imaging.
BGE-102's CV benefits beyond IL-6 reduction?
APJ agonist's body composition benefits with incretins?
Oral BGE-102's impact on bilateral eye disease?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebWASH
Q4 2025 net income up 48%, adjusted EPS up 41%, AUA $7.8B, dividend yield 7.58%. - 6 FebJ
Strong growth, digital innovation, and margin expansion drive robust multi-year financial outlook. - 6 Feb004020
Operating profit rose on cost savings and high-value sales, with major US expansion underway. - 6 FebJOUT
Net sales up 31%, gross margin at 36.6%, and net loss narrowed to $3.3 million. - 6 FebPECO
Record 2025 occupancy and 7% Core FFO growth; 2026 targets 5.5% FFO growth and strong acquisitions. - 6 FebPROV
Q2 FY2026 net income rose 65% year-over-year, with higher margins and strong credit quality. - 6 FebNVDA
AI-driven digital twins and accelerated computing are set to revolutionize industrial design and manufacturing. - 6 FebCDP
2025 FFO/share rose 5.8% to $2.72, with strong leasing and investment; 2026 guidance signals more growth. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and major new contracts in space technology. - 6 FebCRINet loss widened to 7.5m PLN in H1 2024 as revenue fell and R&D costs remained high.
Next BioAge Labs earnings date
Q4 202520 Mar, 2026
BioAge Labs
Next BioAge Labs earnings date
Q4 202520 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioAge Labs Inc. is a biotechnology company focused on developing therapies to extend healthy human lifespan by targeting the biological pathways of aging. The company utilizes a proprietary platform that combines machine learning, genomics, and biomarker analysis to identify and develop drug candidates aimed at treating age-related diseases, such as those affecting muscle health, immune function, and metabolism. BioAge Labs conducts research to address the underlying biological factors of aging with the goal of improving health outcomes in later life. The company is headquartered in Richmond, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage